UNC Eshelman School of Pharmacy

Humana Foundation Announces New Strategy to Eliminate Barriers to Equitable Health and Healthcare

Retrieved on: 
Monday, February 13, 2023
Food, Beverage, Women, Seniors, Retail, Men, Children, Family, Environmental, Social and Governance (ESG), Consumer, Foundation, Professional Services, Fitness & Nutrition, Philanthropy, DEI (Diversity, Equity and Inclusion), General Health, Health, Primary, Secondary, Education, Life, African Americans, Veteran, Humana, Council, NYSE, University of Louisville School of Medicine, Mental, University, Risk, Health equity, UNC Eshelman School of Pharmacy, Senior counsel, Innovation, FoodCorps, Multimedia, Conditional sentence, Quality of life, Nursing, Pharmaceutical industry, Management, Pharmacy

The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced a new strategy to advance health equity by eliminating unjust and unnecessary barriers in health and healthcare.

Key Points: 
  • The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced a new strategy to advance health equity by eliminating unjust and unnecessary barriers in health and healthcare.
  • The Foundation will invest in community-centered partners and evidence-based programs that support seniors, veterans and school-aged children in living connected, healthy lives.
  • View the full release here: https://www.businesswire.com/news/home/20230213005181/en/
    “Every day, people face a multitude of choices that can affect their health and quality of life,” said Tiffany Benjamin, CEO of the Humana Foundation.
  • UNC’s Eshelman Institute will expand a program that pilots solutions brought forward by Black collegiate entrepreneurs to improve community health and nutrition.

Advancements to Explore Recent Breakthroughs in Drug Development for Emerging Diseases

Retrieved on: 
Friday, December 16, 2022
Structural Genomics Consortium, Chapel Hill, Virus, UNC School of Information and Library Science, Innovation, Hearing, School, Partnership, UNC Eshelman School of Pharmacy, Science, UNC School of Medicine, COVID, UNC Gillings School of Global Public Health, DMG, Government, University, Education, University of North Carolina Press, Chapel, Biomedical Advanced Research and Development Authority, Degenerative disease, Vaccine, Pharmacy, Medicine

JUPITER, Fla., Dec. 16, 2022 /PRNewswire-PRWeb/ -- An upcoming segment of Advancements with Ted Danson will focus on innovations in antiviral drugs for emerging diseases.

Key Points: 
  • JUPITER, Fla., Dec. 16, 2022 /PRNewswire-PRWeb/ -- An upcoming segment of Advancements with Ted Danson will focus on innovations in antiviral drugs for emerging diseases.
  • In this segment, viewers will learn how technology is accelerating interdisciplinary team science in an effort to create antiviral drugs for emerging viruses.
  • Hearing from experts in the field, spectators will see how the Rapidly Emerging Antiviral Drug Development Initiative (READDI) is accelerating the pace of antiviral development globally for multiple virus families with the greatest pandemic potential.
  • About Advancements and DMG Productions:
    Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies.

Equashield to Participate in the American Society of Health-System Pharmacist Midyear Clinical Meeting

Retrieved on: 
Monday, December 5, 2022
Transfer, Aerosol, Optical character recognition, Amat, CSTD, Health, UNC Eshelman School of Pharmacy, Convention, Kamiyodo Hakuhō-no-Oka Exhibition Hall, Hospital, NIOSH, FDA, Associate, Body cavity, Pharmacist, Artificial intelligence, Booth, Safety, CE, ASHP, Nursing, Risk, Casino, Healthcare, Pharmacy, Syringe

PORT WASHINGTON, N.Y., Dec. 5, 2022 /PRNewswire/ -- Equashield, a leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs and exclusive proprietor of the only closed-back Syringe Unit, today announced its participation at the ASHP Midyear Clinical Meeting in Las Vegas, Nevada. Equashield will hold demonstrations of its proprietary closed-back Syringe Unit and its automated compounding system, the Equashield PRO, at the ASHP Midyear Clinical Meeting Exhibition Hall.

Key Points: 
  • Equashield will hold demonstrations of the only closed-back CSTD and Equashield PRO at ASHP Midyear Meeting in Las Vegas, Nevada.
  • Equashield will hold demonstrations of its proprietary closed-back Syringe Unit and its automated compounding system, the Equashield PRO, at the ASHP Midyear Clinical Meeting Exhibition Hall.
  • "Equashield is honored to be participating once again in ASHP's Midyear Clinical Meeting," said Marino Kriheli, Product Manager for Equashield.
  • ASHP's Midyear Clinical Meeting is the largest event for pharmacists and pharmacy professionals in the world, with over 20,000 people in attendance.

Rural Caregivers Prefer 'Bad Reaction' to 'Overdose' When Explaining Opioid Antidote

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Human, Communication, Prescription, University, American Indians, Health care, Caregiver, Participation, Risk, Adrenaline, Hospital, Patient safety, Exhibition, Social media, Naloxone, Patient, Epinephrine autoinjector, Language, Black, UNC Eshelman School of Pharmacy, Pharmacist, Society, Opioid overdose, Black people, Doctor of Pharmacy, Confusion, Health, ASHP, Drug, MPH, American Society of Health-System Pharmacists, Pharmacy technician, Pharmaceutical industry, Pharmacy

BETHESDA, Md., Nov. 30, 2022 /PRNewswire/ -- Rural caregivers for patients taking prescription opioids are most comfortable using the term "bad reaction" instead of the potentially stigmatizing term "overdose," and they favor "EpiPen" as the best comparison for describing emergency use of naloxone to reverse effects of opioids, according to a new study scheduled for presentation at the American Society for Health-System Pharmacists Midyear Clinical Meeting in Las Vegas.

Key Points: 
  • "Using the words that caregivers tend to favor may increase their understanding of the drug and its uses."
  • More than a million people have died from opioid overdose since 2000 a disproportionate number in rural areas and 18% of recent opioid deaths involved prescriptions.
  • Researchers interviewed 40 rural caregivers in four states who live with someone at risk for opioid overdose and who had purchased naloxone at a pharmacy.
  • This is the first study to identify rural caregivers' overdose and naloxone terminology preferences while exploring differences by race.

Chemotherapy Drugs from "Rogue" Online Pharmacies Could Endanger Leukemia Patients, Suggests Research in JNCCN

Retrieved on: 
Thursday, July 28, 2022
Online, Patient, CPP, Health care, University, Education, DuckDuckGo, Acute leukemia, Associate professor, Physician, National Comprehensive Cancer Network, CML, Harborside, Twitter, LegitScript, Doctor of Philosophy, Health, Research, Leukemia, Patient safety, UNC Eshelman School of Pharmacy, Medicine, MHS, Safety, Public policy, Michigan Medicine, Cancer, Report, Oncology, Policy, Review, Strathcona County, NCCN, Caregiver, Assistant professor, Journal of the National Comprehensive Cancer Network, URL, Doctor of Pharmacy, Lymphatic system, Hope, Yahoo!, Google, Investor, Decision-making, Bioethics, Pharmaceutical industry, Health insurance, Medical device, Pharmacy

PLYMOUTH MEETING, Pa., July 28, 2022 /PRNewswire/ -- Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network. A survey of online pharmacies claiming to sell the oral chemotherapy drug imatinib found that only three of the 44 identified English-language sites that shipped within the United States were certified through the LegitScript online pharmacy monitoring service. A full 52% were classified as "rogue" pharmacies that might operate without a license, sell counterfeit or expired products, steal users' payment information, or reject important safety precautions like requiring a prescription for potentially hazardous medications. 

Key Points: 
  • A new study finds a majority of online pharmacies selling the chronic myeloid leukemia therapy imatinib are uncertified and could be operating unsafely.
  • Tyrosine kinase inhibitors like imatinib have made chronic myeloid leukemia (CML) a manageable condition rather than a fatal one.
  • Yet to work optimally, the drug must be taken for the rest of a patient's life and with high compliance.
  • Complimentary access to " Online Pharmacy Accessibility of Imatinib, An Oral Chemotherapy Medication " is available until October 10, 2022.

AESARA to welcome the incoming class of five fellows and a visiting scientist.

Retrieved on: 
Friday, July 8, 2022
Clinical Trials, Education, Cardiology, Biotechnology, Alternative Medicine, Women, AIDS, Other Science, Health, Research, Consumer, Science, Other Health, FDA, Diabetes, Managed Care, Pharmaceutical, General Health, Oncology, Mental Health, Medical Devices, Infectious Diseases, Hospitals, Genetics, University, Robertson Scholars Program, LinkedIn, CEO, UNC, MHS, Division, UNC Eshelman School of Pharmacy, Partnership, Doctor of Pharmacy, Market access, University, Doctor of Philosophy, Solution, Associate, Health, Twitter, Education, Program, University of North Carolina, Medicine, Pharmacy

Denise and Ashik are joining AESARA as part of the Market Access and Health Informatics Fellowship Program between University of North Carolina and AESARA; Fadi and Amanda mark the first generation of the AESARA PAIDEIA Fellowship Program.

Key Points: 
  • Denise and Ashik are joining AESARA as part of the Market Access and Health Informatics Fellowship Program between University of North Carolina and AESARA; Fadi and Amanda mark the first generation of the AESARA PAIDEIA Fellowship Program.
  • Additionally, Phoenix Riley, PharmD, MSCR will join AESARA as a visiting scientist under AESARA-sponsored one-year Market Acess/Health Economics Outcomes Research program aimed to build upon previous academic and real-world research experiences.
  • Sissi Pham, CEO of AESARA, said, "This is the largest class of incoming scholars for AESARA to-date, and it speaks volumes to our commitment and investment into the next generation of health services researchers and Market Access professionals.
  • AESARA is a market access agency with a focused purpose to impact healthcare decision-making to improve peoples lives.

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Lung, EC50, University of North Carolina at Greensboro, Kruskal–Wallis one-way analysis of variance, Innovation, Virus, NASDAQ, University, ICAR, UNC Eshelman School of Pharmacy, Safety, Combination therapy, Respiratory disease, Severe acute respiratory syndrome coronavirus 2, International Conference on Emerging Infectious Diseases, BARDA, Antiviral Research, Conference, Patient, Epithelium, CMX521, Degenerative disease, Infection, Doctor of Philosophy, Chapel Hill, Pharmaceutical industry, Pharmacy

This agent is particularly interesting in that it has demonstrated an attractive safety profile in a prior Phase 1 dose escalation trial in healthy volunteers.

Key Points: 
  • This agent is particularly interesting in that it has demonstrated an attractive safety profile in a prior Phase 1 dose escalation trial in healthy volunteers.
  • In vitro, CMX521 was shown to inhibit SARS-CoV-2 replication in primary human airway epithelial cells with an average EC50 of 0.9M.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • Forward-looking statements include those relating to, among other things, the results of current and future preclinical and clinical testing of CMX521.

SAS and UNC-Chapel Hill partner to accelerate antiviral drug development

Retrieved on: 
Tuesday, September 14, 2021
Global health, Student, Education, School, District, Government, Drug discovery, SAS Institute Inc v World Programming Ltd, University, University of North Carolina, Drug development, Chapel Hill, Patient, Association of American Universities, The arts, Clinical trial, SAS, Pandemic, University of North Carolina at Chapel Hill, Association, Therapy, POWER, Machine learning, SAS Institute, COVID-19, UNC School of Dentistry, Partnership, University of Pennsylvania College of Arts & Sciences, UNC Eshelman School of Pharmacy, Name, Intelligence, Research, College, Faculty, Data analysis, Pharmaceutical industry, Satellite navigation device

The partnership is focused on the work oftheUniversity's Rapidly Emerging Antiviral Drug Development Initiative (READDI) which is developing broad spectrum antiviral drugs to have on the shelf to prevent future pandemics.

Key Points: 
  • The partnership is focused on the work oftheUniversity's Rapidly Emerging Antiviral Drug Development Initiative (READDI) which is developing broad spectrum antiviral drugs to have on the shelf to prevent future pandemics.
  • "SAS strives to create a healthier world through analytics," said SAS Chief Executive Officer Jim Goodnight.
  • While the initial focus of the joint team is on addressing new treatments for COVID-19 ,READDI and SAS will continue to work together to meaningfully accelerate drug discovery for other antiviral drugs.
  • SAS and all other SAS Institute Inc.productor service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries.

Deerfield Management, UNC Eshelman School of Pharmacy Announce First Educational Collaboration

Retrieved on: 
Wednesday, March 31, 2021
Research, Professional services, Pharmaceutical, Training, Other Education, Continuing, University, Education, Science, Other Professional Services, Biotechnology, Health, Consulting, Angela Kashuba, UNC Eshelman School of Pharmacy, Eshelman, Pharmacy, Deerfield, Deerfield, UNC Eshelman School of Pharmacy

Deerfield Management Company (Deerfield), a healthcare investment management firm focused on advancing healthcare through investment, information and philanthropy, and the UNC Eshelman School of Pharmacy are thrilled to announce a first-of-its-kind educational-based collaboration that features a new certificate program and kick-off seminar.

Key Points: 
  • Deerfield Management Company (Deerfield), a healthcare investment management firm focused on advancing healthcare through investment, information and philanthropy, and the UNC Eshelman School of Pharmacy are thrilled to announce a first-of-its-kind educational-based collaboration that features a new certificate program and kick-off seminar.
  • Our collaboration with Deerfield will fill a much-needed gap by training on specific competencies required to advance discoveries to the market, said Angela Kashuba, dean of the UNC Eshelman School of Pharmacy.
  • The UNC Eshelman School of Pharmacy is a world-renowned academic institution and is ranked the No.
  • The UNC Eshelman School of Pharmacy, based in Chapel Hill, N.C., is an internationally recognized leader in pharmacy practice, education, and research.